Northland analyst Carl Byrnes initiated coverage of TriSalus Life Sciences (TLSI) with an Outperform rating and $12.50 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI:
Questions or Comments about the article? Write to editor@tipranks.com